Rhode Island is contested, and we treat it as a state where video cannot start testosterone. The binding physician rule, 216-RICR-40-05-1 § 1.5.9(H)(2), is silent on in-person exams and bars asynchronous care. The Board’s posted telemedicine guideline says prescribing controlled substances “without an established in-person physician-patient relationship is prohibited.” Testosterone is Schedule III. Build for the guideline.
That reading holds as of September 2026, while the federal DEA flexibilities under 21 C.F.R. § 1307.41 run through December 31, 2026. The federal waiver removes a federal in-person requirement. It does not answer what the Rhode Island Board expects. For the other states, see telehealth testosterone by state.
What the binding rule says
The Department of Health’s physician rule was last amended effective August 26, 2026. Its telemedicine standard, in § 1.5.9(H)(2), says three things.
- Online treatment, “including issuing a prescription via electronic means, will be held to the same standards of appropriate practice as those in face-to-face settings.”
- A prescription “based solely on an online questionnaire without an appropriate evaluation” is unprofessional conduct.
- “Asynchronous evaluation of a patient, without contemporaneous real-time, interactive exchange between the physician and patient, is not appropriate.”
That is the whole telemedicine section. It says nothing about controlled substances and nothing about an in-person visit. Read alone, it would allow a live video start.
What the Board’s guideline says
The Board of Medical Licensure and Discipline also publishes Guidelines for the Appropriate Use of Telemedicine and the Internet in Medical Practice, hosted on the Department of Health site. For most care, it is permissive: a relationship forms when physician and patient agree, “whether or not there has been an in-person encounter.”
Controlled substances are the stated exception: “The BMLD specifically highlights that prescribing controlled substances without an established in-person physician-patient relationship is prohibited.” The only carve-out is for “a covering physician” with “an established coverage agreement,” where “the quantity reflects the prescription is for a short duration.”
The document is undated. Its file metadata points to March 2013. It has not been withdrawn, and the rule’s language on face-to-face standards and questionnaires tracks the guideline almost word for word.
| 216-RICR-40-05-1 § 1.5.9(H)(2) | Board telemedicine guideline | |
|---|---|---|
| Legal status | Promulgated regulation | Board guidance |
| Current as of | Effective August 26, 2026 | Undated, still posted |
| In-person for controlled substances | Not addressed | Required (“prohibited” without it) |
| Asynchronous evaluation | “Not appropriate” | Questionnaire-only is unprofessional conduct |
| Exception | None stated | Covering physician, coverage agreement, short supply |
Why we follow the guideline
A regulation that says nothing does not overrule guidance that says something. The two documents do not conflict. The rule sets a floor for all telemedicine, and the guideline adds a specific line for controlled substances. The Board that wrote the guideline is the Board that disciplines, and unprofessional conduct under § 1.5.9 is broad enough to reach a practice the Board has publicly called prohibited.
The cost of being wrong falls on the prescriber’s license. Until the Board withdraws or revises the guideline, or says in writing that it no longer applies, we treat an in-person relationship as required before the first testosterone prescription.
The path that works in Rhode Island
This sequence satisfies both documents:
- License the prescriber in Rhode Island and hold a Rhode Island controlled substance registration plus DEA registration. R.I. Gen. Laws § 21-28-3.02(a) requires state registration for anyone who prescribes controlled substances in the state.
- Confirm PDMP access. Under § 21-28-3.32, registration with the prescription monitoring database is a condition of controlled substance authority. The statute’s mandatory pre-prescription review is written for opioids. Checking before a testosterone start is still good practice.
- Hold the first visit in person with the prescribing physician at a Rhode Island site: history, physical exam, labs and a written plan.
- Move follow-ups to live video. The rule bars asynchronous evaluation, so no questionnaire refills and no chat-only check-ins.
- Refer back in person whenever the clinical picture calls for it, and document the referral. The guideline treats a failure to refer as unprofessional conduct.
- Write the coverage agreement so a covering physician can bridge a short supply inside the guideline’s exception.
The guideline and the physician rule govern physicians. Nurse practitioner prescribing sits with the nursing board, and we have not verified its position. Apply the same in-person step to a nurse practitioner until counsel says otherwise.
If you run a med spa in the state, the facility rules add their own layer. Rhode Island licenses the med spa itself and restricts who may work there, covered on medical director in Rhode Island and good faith exams in Rhode Island.
How MDside handles Rhode Island
MDside is LegitScript certified. Its testosterone visits are synchronous, live video with the prescriber, and offered only in states whose rules allow them. Rhode Island’s Board requires an in-person relationship first, so MDside does not start Rhode Island patients by video. That is stricter than the regulation alone requires, and it is deliberate. The hormone therapy program applies the in-person step here, and the asynchronous telehealth map shows why Rhode Island never gets a questionnaire path.
What this means for you
Do not route new Rhode Island testosterone patients to a home-video intake. Build the first visit around a Rhode Island location where the prescriber sees the patient in person, then run follow-ups by live video. Confirm each prescriber’s state controlled substance registration before the first prescription. Ask counsel to request a written Board position if you want to rely on the silent rule, and track the federal December 31, 2026 date.
Related reading
Frequently asked questions
Can you get testosterone through telehealth in Rhode Island?
It is contested. The binding rule, 216-RICR-40-05-1 § 1.5.9(H)(2), allows real-time telemedicine and does not mention in-person exams. The Board’s telemedicine guideline says prescribing controlled substances without an established in-person relationship is prohibited. Testosterone is Schedule III, so the safe path is an in-person first visit, then live video.
Is Rhode Island’s telemedicine guideline binding?
It is Board guidance, never promulgated as a regulation. It is also the published position of the Board of Medical Licensure and Discipline, which disciplines physicians for unprofessional conduct. The guideline is undated and has not been withdrawn. Until the Board revises it or says otherwise in writing, treat its controlled substance line as the standard you will be measured against.
Can Rhode Island doctors prescribe by online questionnaire?
No. Under 216-RICR-40-05-1 § 1.5.9(H)(2), a prescription based solely on an online questionnaire without an appropriate evaluation is unprofessional conduct, and asynchronous evaluation without a real-time, interactive exchange is not appropriate. Every telehealth visit that leads to a prescription needs live interaction between physician and patient.
Do the DEA telehealth flexibilities change the Rhode Island answer?
No. The DEA flexibilities under 21 C.F.R. § 1307.41 run through December 31, 2026 and waive only the federal in-person requirement. They say nothing about the Rhode Island Board’s guideline, and they do not replace the Rhode Island controlled substance registration a prescriber needs in addition to DEA.
—
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.